With Biocon Biologics having previously integrated its acquisition of Viatris’s biosimilars business in emerging markets and North America, the firm has now completed integration in Europe. In an exclusive interview, CEO Shreehas Tambe tells Generics Bulletin what this means for the company and reveals the opportunities it perceives ahead.
“Unless you control the business directly, you do not have control over your destiny. That was very clear to us from the beginning.”
This is how Biocon Biologics CEO and managing director Shreehas Tambe describes the significance of the Indian firm’s $3bn...
Create an account to read this article
Already a subscriber?
Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.
Shanghai Henlius Biotech has received EMA GMP certification for its HLX14 and HLX11 biosimilar production lines, paving the way for faster market entry in the EU and reinforcing its global manufacturing credentials.
Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.
Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.
Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.
